



## Canadian spotlight 2.2: Key additions from the second half of February 2021

In the second half of February, contributing evidence-synthesis teams have shared with us 10 newly completed evidence syntheses and six questions that they have newly taken on, which are listed in the table below. One of these syntheses provide insights across all four domains of the COVID-END taxonomy (public-health measures, clinical management, health-system arrangements, and economic and social responses) and one synthesis provides insight across two domains (public-health measures and economic and social responses). The remaining focus on clinical management (n=7) and economic and social responses (n=1). The six synthesis questions currently being addressed by teams focus on public-health measures (n=4) and clinical management (n=2).

Taxonomy section	Title	Type of product	Date of last search (and publication)	Evidence synthesis team
<ul style="list-style-type: none"> <li>Public-health measures</li> <li>Clinical management</li> <li>Health-system arrangements</li> <li>Economic and social responses</li> </ul>	<a href="#">COVID-19 living evidence profile #1 (version 4): What is known about anticipated COVID-19 vaccine roll-out elements?</a>	Update to a living evidence profile	2021-02-25 (published 2021-02-26)	McMaster Health Forum   COVID-END Secretariat
<ul style="list-style-type: none"> <li>Public-health measures</li> <li>Economic and social responses</li> </ul>	<a href="#">Interventions preventing or controlling the spread of COVID-19 in workplaces</a>	Briefing note	Not stated (published 2021-02-11)	Research, Analysis and Evaluation Branch (RAEB), Ministry of Health – Evidence Synthesis Network
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	What are best practices for risk communication and strategies to mitigate risky behaviours? <i>(to be published)</i>	Question currently being addressed in a rapid review	Not yet available	National Collaborating Centre for Methods and Tools
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	What is known about how long the virus can survive with potential for infection on surfaces? <i>(to be published)</i>	Question currently being	Not yet available	National Collaborating Centre for

		addressed in a rapid review		Methods and Tools
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<p>In the community setting where nonmedical masks are used, what is the evidence (effectiveness, safety and filtration properties) for the use of two non-medical masks (or non-medical masks with multiple layers) to prevent COVID-19 transmission?</p> <ul style="list-style-type: none"> <li>Are there ways to optimize fit to improve filterability and reduce transmission?</li> <li>Is there evidence that variant strains are more readily transmitted in spite of good masking practices?</li> </ul> <p><i>(synthesis not yet completed)</i></p>	Question currently being addressed in a rapid review	Not yet available	Alberta Health Services
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<p>Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals? If so, how large is the risk, in comparison to unvaccinated people?</p> <p><i>(synthesis not yet completed)</i></p>	Question currently being addressed in a living review	Not yet available	Health Technology Assessment Unit, O'Brien Institute of Public Health, University of Calgary
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Ongoing trials for drugs in the prevention and treatment of COVID-19</a></p>	Update to living review	2021-02-19 (published 2021-02-25)	Canadian Agency for Drugs and Technologies in Health (CADTH)
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Remdesivir: Evidence review and appraisal</a></p>	Update to living review	Not stated (published 2021-02-19)	Canadian Agency for Drugs and Technologies in Health (CADTH)
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Ivermectin for the treatment and prevention of COVID-19</a></p>	Rapid review	Not stated (published 2021-02-17)	Canadian Agency for Drugs and Technologies in Health (CADTH)
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Ivermectin in the treatment and prevention of COVID-19</a></p>	Rapid review	2021-01-11 (published 2021-02-02)	Alberta Health Services
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Low molecular weight heparin for thromboprophylaxis of COVID-19 positive long-term care home residents</a></p>	Briefing note	Not stated (published 2021-02-11)	RAEB, Ministry of Health –

				Evidence Synthesis Network
• Clinical management	<a href="#">Respiratory device fit for individuals with facial hair</a>	Rapid review	Not stated (published 2021-02-10)	Canadian Agency for Drugs and Technologies in Health (CADTH)
• Clinical management	<a href="#">Prone positioning for awake, non-intubated patients with SARS-COV-2 pneumonia</a>	Rapid review	2021-01-08 (published 2021-02-03)	Alberta Health Services
• Clinical management	What is the evidence for colchicine as a treatment for COVID-19? Are there risks associated with the use of colchicine for treatment of COVID-19? <i>(to be published)</i>	Question currently being addressed in a rapid review	Not available yet	Alberta Health Services
• Clinical management	What is the optimal strategy for clearing patients who were infected with COVID-19 so they fill standard criteria to be a candidate for cancer treatment? <i>(to be published)</i>	Question currently being addressed in a rapid review	Not yet available	Alberta Health Services
• Economic and social responses	<a href="#">Paid sick leave benefits during the COVID-19 pandemic</a>	Briefing note	Not stated (published 2021-02-17)	RAEB, Ministry of Health – Evidence Synthesis Network